# Filing Detail

Form S-4/A - Registration of securities, business combinations: [Amend]
SEC Accession No. 0001104659-23-002376
Filing Date
2023-01-10
Accepted
2023-01-09 20:04:01
Documents
54

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | S-4/A | tm2227887-11_s4a.htm | S-4/A | 9892557
2 | EXHIBIT 10.35 | tm2227887d12_ex10-35.htm | EX-10.35 | 117771
3 | EXHIBIT 23.1 | tm2227887d12_ex23-1.htm | EX-23.1 | 1989
4 | EXHIBIT 23.3 | tm2227887d12_ex23-3.htm | EX-23.3 | 1483
5 | EXHIBIT 99.4 | tm2227887d12_ex99-4.htm | EX-99.4 | 2999
6 | GRAPHIC | lg_sesenbio-4c.jpg | GRAPHIC | 26508
7 | GRAPHIC | lg_carismatherapeutics-4c.jpg | GRAPHIC | 52313
8 | GRAPHIC | lg_mackenziepartners-bw.jpg | GRAPHIC | 19520
9 | GRAPHIC | tm2227887d8-tbl_pipelin4c.jpg | GRAPHIC | 123685
10 | GRAPHIC | tm2227887d8-tbl_oncolog4c.jpg | GRAPHIC | 151263
11 | GRAPHIC | tm2227887d8-fc_problem4c.jpg | GRAPHIC | 301235
12 | GRAPHIC | tm2227887d1-pht_tumor4c.jpg | GRAPHIC | 74270
13 | GRAPHIC | tm2227887d1-lc_human4c.jpg | GRAPHIC | 34969
14 | GRAPHIC | tm2227887d4-lc_contrl4c.jpg | GRAPHIC | 73816
15 | GRAPHIC | tm2227887d4-lc_reprogra4c.jpg | GRAPHIC | 183212
16 | GRAPHIC | tm2227887d1-pht_macrop4clr.jpg | GRAPHIC | 251991
17 | GRAPHIC | tm2227887d1-tbl_exvivo4c.jpg | GRAPHIC | 57154
18 | GRAPHIC | tm2227887d4-tbl_pipelin4c.jpg | GRAPHIC | 128200
19 | GRAPHIC | tm2227887d1-pht_key4c.jpg | GRAPHIC | 17906
20 | GRAPHIC | tm2227887d1-org_clinic4c.jpg | GRAPHIC | 76428
21 | GRAPHIC | tm2227887d4-bc_adverse4c.jpg | GRAPHIC | 688092
22 | GRAPHIC | tm2227887d4-lc_rapidly4c.jpg | GRAPHIC | 927375
23 | GRAPHIC | tm2227887d1-bc_single4clr.jpg | GRAPHIC | 25751
24 | GRAPHIC | tm2227887d4-bc_mostpreva4c.jpg | GRAPHIC | 1120837
25 | GRAPHIC | tm2227887d4-bc_frequen4c.jpg | GRAPHIC | 883842
26 | GRAPHIC | tm2227887d4-tbl_selct4c.jpg | GRAPHIC | 175146
27 | GRAPHIC | tm2227887d4-lc_pt4comp4c.jpg | GRAPHIC | 835610
28 | GRAPHIC | tm2227887d1-lc_asses4c.jpg | GRAPHIC | 50172
29 | GRAPHIC | tm2227887d1-lc_itcar4c.jpg | GRAPHIC | 23415
30 | GRAPHIC | tm2227887d1-pht_profnd4clr.jpg | GRAPHIC | 177151
31 | GRAPHIC | tm2227887d1-bc_119ct4c.jpg | GRAPHIC | 169909
32 | GRAPHIC | tm2227887d4-lc_ct1119a5494c.jpg | GRAPHIC | 631092
33 | GRAPHIC | tm2227887d1-lc_carmno4c.jpg | GRAPHIC | 64256
34 | GRAPHIC | tm2227887d1-bc_cyto4c.jpg | GRAPHIC | 121448
35 | GRAPHIC | tm2227887d1-lc_polar4c.jpg | GRAPHIC | 35856
36 | GRAPHIC | tm2227887d4-lc_persis4c.jpg | GRAPHIC | 182651
37 | GRAPHIC | tm2227887d4-lc_tumor4c.jpg | GRAPHIC | 105907
38 | GRAPHIC | tm2227887d4-fc_antibody4c.jpg | GRAPHIC | 1517204
39 | GRAPHIC | tm2227887d1-lc_poten4c.jpg | GRAPHIC | 34644
40 | GRAPHIC | tm2227887d1-pht_ipsc4clr.jpg | GRAPHIC | 68351
41 | GRAPHIC | tm2227887d1-bc_icar4c.jpg | GRAPHIC | 32157
42 | GRAPHIC | tm2227887d4-lc_ipscmacs4c.jpg | GRAPHIC | 55202
43 | GRAPHIC | tm2227887d1-pht_myloid4clr.jpg | GRAPHIC | 121994
44 | GRAPHIC | tm2227887d4-lc_lnp4c.jpg | GRAPHIC | 71874
45 | GRAPHIC | tm2227887d4-lc_2lnp4c.jpg | GRAPHIC | 66248
46 | GRAPHIC | tm2227887d4-lc_3lnp4c.jpg | GRAPHIC | 83140
47 | GRAPHIC | tm2227887d4-lc_4lnp4c.jpg | GRAPHIC | 70114
48 | GRAPHIC | tm2227887d4-lc_5lnp4c.jpg | GRAPHIC | 64773
49 | GRAPHIC | tm2227887d4-lc_6lnp4c.jpg | GRAPHIC | 81395
50 | GRAPHIC | tm2227887d1-pht_reprobw.jpg | GRAPHIC | 29917
51 | GRAPHIC | tm2227887d1-lc_macro4c.jpg | GRAPHIC | 54331
52 | GRAPHIC | tm2227887d4-fc_carm4c.jpg | GRAPHIC | 777890
53 | GRAPHIC | lg_svbsecurities-4c.jpg | GRAPHIC | 31277
54 | GRAPHIC | ft_svbsecurities-4c.jpg | GRAPHIC | 38020
| Complete submission text file | 0001104659-23-002376.txt |  | 24919557

Mailing Address 245 FIRST STREET SUITE 1800 CAMBRIDGE MA 02142
Business Address 245 FIRST STREET SUITE 1800 CAMBRIDGE MA 02142 617-444-8550
Sesen Bio, Inc. (Filer) CIK: 0001485003 (see all company filings)

EIN.: 262025616 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-4/A | Act: 33 | File No.: 333-267891 | Film No.: 23519486
SIC: 2834 Pharmaceutical Preparations